/

ABOS

Acumen Pharmaceuticals, Inc.Closed

1.82−0.21 −10.15%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.84 +1.38%

Open

2.00

Prev close

2.02

Day range

1.812.00

52-week range

1.503.60

Volume

646.04K1.48×

Mkt cap

131.26M

P/E ttm

—

Fwd P/E

-1.27

EPS ttm

-1.64

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−49.58%

Price Chart

Yahoo Finance · delayed

ABOSOct 13, 2026O 2.00H 2.00L 1.81C 1.82−0.20 (−10.15%)Vol 646.10K

SMA 502.59
SMA 2002.50

1Y change −14.39% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ABOS Acumen Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.59%
1 month: −37.84%
3 months: −28.26%
6 months: −32.28%
Year to date: −13.98%
1 year: −14.39%

Valuation & ownership

Market cap: 131.26M
Enterprise value: 52.70M
P/E (ttm): —
Forward P/E: -1.27
PEG ratio: —
Price / book: 2.29
Price / sales (ttm): —
EV / EBITDA: -0.50
EPS (ttm): -1.64
EPS (forward): -1.43
Beta (5y monthly): 0.33
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 72.32M
Float: 37.05M
Short % of float: 6.11%
Short ratio (days): 6.26
Held by insiders: 6.79%
Held by institutions: 66.59%
Avg volume (3m): 436.18K
50-day average: 2.60
200-day average: 2.51
52-week change: −14.39%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 28.6
vs 50-day SMA: −29.93%
vs 200-day SMA: −27.54%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.45%
Realised vol (20d, ann.): 80.8%
From 52-week high: −49.58%
From 52-week low: +21.00%

ANR

Analyst Consensus

5 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

7.60

+318.73% implied

Low 5.00Median 8.00High 10.00

Recommendation trend

Now6 / 0 / 0
1m ago6 / 0 / 0
2m ago

DES

About Acumen Pharmaceuticals, Inc.

Yahoo Finance profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 60
Headquarters: Newton, MA, United States
Website: acumenpharm.com
Officers: Mr. Daniel J. O'Connell M.B.A. CEO & Director
Dr. James Doherty Ph.D. President & Chief Development Officer
Mr. Matt Zuga CFO & Chief Business Officer
Dr. Grant A. Krafft Ph.D. Co-Founder

SEAS

Seasonality · ABOS

2021–2026 · monthly returns

Strongest month Jul +31.66%Weakest month Mar −19.08%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	23.2	20.8	-24.8	1.3	8.8	2.7	-19.5	32.6	-22.1	-18.2			−14.0%
2025	-12.8	-14.7	-14.1	2.7	-9.7	13.7	20.7	-2.9	25.7	29.2	-14.9	12.2	+22.7%
2024	-17.2	35.5	-6.0	-20.5	-8.7	-17.7	36.4	-17.0	-9.5	16.1	-21.2	-24.2	−55.2%
2023	21.7	-19.8	-23.0	-4.9	27.7	-2.4	53.8	-18.6	-31.1	-54.9	28.3	60.0	−28.9%
2022	-24.3	14.5	-33.3	-1.3	-8.3	32.8	15.7	4.6	76.3	-31.0	-17.9	-4.9	−20.1%
2021								15.8	-17.1	-5.5	-43.8	-14.4	−56.3%

INSD

Insider Activity · ABOS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

303.5K shares

Sells, 6 months

38.7K shares

Net shares

+264.8K

Net change in insider shares

+5.70%

Date	Insider	Transaction	Shares	Value
Jun 16, 2026	Porter Derrell PDirector	Conversion of Exercise of derivative security at price 1.07 per share.	19.5K	$20.86K
Jun 16, 2026	Porter Derrell PDirector	Sale at price 2.32 - 2.34 per share.	32.3K	$75.24K
Jun 8, 2026	Fountain Nathan BDirector	Sale at price 2.23 per share.	6.4K	$14.27K
Jun 2, 2026	Drapkin Kimberlee Cobleigh CpaDirector	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Jun 2, 2026	Golumbeski George SDirector	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Jun 2, 2026	Ives Jeffrey LDirector	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Jun 2, 2026	Porter Derrell PDirector	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Jun 2, 2026	Stalfort John ADirector	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Jun 2, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Jun 2, 2026	Fountain Nathan BDirector	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Jun 2, 2026	Stoppel LauraDirector	Stock Award(Grant) at price 0.00 per share.	35.5K	—
Mar 15, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 3.30 per share.	6.06M	$20.00M
Mar 5, 2026	Meisner Derek MOfficer	Conversion of Exercise of derivative security at price 1.85 per share.	2.1K	$3.87K
Mar 5, 2026	Meisner Derek MOfficer	Sale at price 3.26 per share.	2.1K	$6.81K
Feb 26, 2026	Meisner Derek MOfficer	Conversion of Exercise of derivative security at price 1.85 per share.	9.4K	$17.40K
Feb 26, 2026	Meisner Derek MOfficer	Sale at price 3.01 per share.	9.4K	$28.31K
Jan 27, 2026	Meisner Derek MOfficer	Conversion of Exercise of derivative security at price 1.85 per share.	17.8K	$32.85K
Jan 27, 2026	Meisner Derek MOfficer	Sale at price 2.08 - 3.00 per share.	17.8K	$39.39K
Jan 22, 2026	Meisner Derek MOfficer	Sale at price 1.81 - 1.90 per share.	8.9K	$16.72K
Jan 21, 2026	William Matthew ZugaChief Financial Officer	Sale at price 1.81 - 1.86 per share.	4.2K	$7.61K

13F

Investors Holding ABOS

latest 13F filings of 29 followed managers

Investors holding ABOS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.8M	0.00%	675.02K	+42%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ABOS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ABOS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Acumen Pharmaceuticals, Inc.

Seasonality · ABOS

Insider Activity · ABOS

Congress Trades · ABOS

Investors Holding ABOS

Investors Holding ABOS

Congress Trades · ABOS

Seasonality · ABOS

Insider Activity · ABOS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Acumen Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News